BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 28334622)

  • 1. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
    Martin JA; Warner RR; Wisnivesky JP; Kim MK
    Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Fang C; Wang W; Feng X; Sun J; Zhang Y; Zeng Y; Wang J; Chen H; Cai M; Lin J; Chen M; Chen Y; Li Y; Li S; Chen J; Zhou Z
    Br J Cancer; 2017 Nov; 117(10):1544-1550. PubMed ID: 28949958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.
    Luo G; Javed A; Strosberg JR; Jin K; Zhang Y; Liu C; Xu J; Soares K; Weiss MJ; Zheng L; Wolfgang CL; Cives M; Wong J; Wang W; Sun J; Shao C; Wang W; Tan H; Li J; Ni Q; Shen L; Chen M; He J; Chen J; Yu X
    J Clin Oncol; 2017 Jan; 35(3):274-280. PubMed ID: 27646952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of AJCC/UICC and WHO-2010 classifications for GEP-NEN in Chinese patients.
    Ye BX; Heng D; Jiang LQ; Wang Y; Zhang HJ; Lin L
    J Dig Dis; 2015 May; 16(5):264-71. PubMed ID: 25707298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
    Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
    Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients.
    Teo R; Goh BKP; Tai DWM; Allen JC; Lim TKH; Hwang JSG; Tan DM; Lee SY; Chan CY; Cheow PC; Chow PKH; Ooi LLPJ; Chung AYF; Ong S
    Surgery; 2017 May; 161(5):1235-1245. PubMed ID: 28111046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
    Anlauf M
    Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
    Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
    Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
    Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
    Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 20. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.